MABSOT

Development of OPN-305 as an orphan drug for the treatment of Delayed Graft Function post solid organ transplantation

 Coordinatore OPSONA THERAPEUTICS LIMITED 

 Organization address address: ROOM 2 13 FIRST FLOOR I M M TRINITY CENTRE FOR HEALTH SICENCE ST JAMES HOSPITAL
city: DUBLIN

contact info
Titolo: Ms.
Nome: Mary
Cognome: Reilly
Email: send email
Telefono: +353 1 6770223
Fax: +353 1 6778949

 Nazionalità Coordinatore Ireland [IE]
 Sito del progetto http://www.mabsot.eu/
 Totale costo 7˙844˙900 €
 EC contributo 5˙929˙064 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2010-single-stage
 Funding Scheme CP-FP
 Anno di inizio 2010
 Periodo (anno-mese-giorno) 2010-12-01   -   2014-09-30

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    OPSONA THERAPEUTICS LIMITED

 Organization address address: ROOM 2 13 FIRST FLOOR I M M TRINITY CENTRE FOR HEALTH SICENCE ST JAMES HOSPITAL
city: DUBLIN

contact info
Titolo: Ms.
Nome: Mary
Cognome: Reilly
Email: send email
Telefono: +353 1 6770223
Fax: +353 1 6778949

IE (DUBLIN) coordinator 2˙232˙195.00
2    KING'S COLLEGE LONDON

 Organization address address: Strand
city: LONDON
postcode: WC2R 2LS

contact info
Titolo: Mr.
Nome: Paul
Cognome: Labbett
Email: send email
Telefono: 442078000000
Fax: 442078000000

UK (LONDON) participant 1˙051˙131.00
3    INSTITUT CATALA DE LA SALUT

 Organization address address: GRAN VIA DE LES CORTS CATALANES 587
city: BARCELONA
postcode: 8007

contact info
Titolo: Ms.
Nome: Laia
Cognome: Lagunas
Email: send email
Telefono: +34 932607226

ES (BARCELONA) participant 461˙648.00
4    KATHOLIEKE UNIVERSITEIT LEUVEN

 Organization address address: Oude Markt 13
city: LEUVEN
postcode: 3000

contact info
Titolo: Dr.
Nome: Elke
Cognome: Lammertyn
Email: send email
Telefono: 3216320621
Fax: 3216326515

BE (LEUVEN) participant 449˙088.00
5    ACADEMISCH ZIEKENHUIS GRONINGEN

 Organization address address: Hanzeplein 1
city: GRONINGEN
postcode: 9713 GZ

contact info
Titolo: Ms.
Nome: Johanna M
Cognome: Van Apeldoorn
Email: send email
Telefono: 31503633040
Fax: 31503632883

NL (GRONINGEN) participant 443˙599.00
6    UNIVERSITY OF NEWCASTLE UPON TYNE

 Organization address address: Kensington Terrace 6
city: NEWCASTLE UPON TYNE
postcode: NE1 7RU

contact info
Titolo: Ms.
Nome: Aleona
Cognome: Blinova
Email: send email
Telefono: 441913000000
Fax: 441913000000

UK (NEWCASTLE UPON TYNE) participant 427˙434.00
7    Nome Ente NON disponibile

 Organization address address: Videnska 1958/9
city: PRAGUE 4
postcode: 14021

contact info
Titolo: Mr.
Nome: Tomas
Cognome: Linhart
Email: send email
Telefono: 420261000000
Fax: 420261000000

CZ (PRAGUE 4) participant 353˙271.00
8    ALMAC DIAGNOSTICS LIMITED

 Organization address address: SEAGOE INDUSTRIAL ESTATE 20
city: CRAIGAVON
postcode: BT63 5QD

contact info
Titolo: Ms.
Nome: Valerie
Cognome: Cooke
Email: send email
Telefono: 442838000000
Fax: +4428 38398676

UK (CRAIGAVON) participant 261˙511.00
9    EURAM LIMITED

 Organization address address: "Tower House, Lucy Tower Street"
city: LINCOLN
postcode: LN1 1XW

contact info
Titolo: Mr.
Nome: Andrew
Cognome: Banasik
Email: send email
Telefono: 441160000000
Fax: 441160000000

UK (LINCOLN) participant 249˙187.00
10    FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE

 Organization address address: AVENIDA GRAN VIA HOSPITALET 199-203
city: L'HOSPITALET DE LLOBREGAT
postcode: 8908

contact info
Titolo: Ms.
Nome: Victoria
Cognome: Cochrane
Email: send email
Telefono: 34932607226
Fax: 34932607224

ES (L'HOSPITALET DE LLOBREGAT) participant 0.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

rejection    renal    treatment    prolonged    hospitalisation    function    omp    antibody    transplantation    delayed    dialysis    solid    dgf    organ    individuals    opn    graft   

 Obiettivo del progetto (Objective)

'Delayed graft function (DGF) is defined as the need for dialysis within seven days of renal transplantation (DGF promotes allograft rejection, requires prolonged dialysis and hospitalisation, and increases the likelihood of graft failure and ultimately the duration of renal graft survival-expectancy. The incidence of DGF occurs in 21-44% of cases following cadaveric renal graft. Several rare diseases, particularly those of genetic origin, are associated with the requirement for solid organ transplantation as the disease progresses. At Opsona Therapeutics we have developed a novel antibody (OPN-305) which has received OMP designation (EU/3/09/638) for use in the prevention of DGF. The scientific basis of this development is the inhibition of Toll-like receptor 2 (TLR2)-mediated ischaemic reperfusion injury which has a pivotal role in the pathogenesis of DGF and its sequelae. The MABSOT project is designed to progress the development of this OMP through Phase I and II clinical trial. The successful completion of the programme will allow the continued development of OPN-305 as an OMP for the treatment of DGF in a range of solid organ transplant situations. OPN-305 development will have significant benefit to these patients and health care providers in reducing the prolonged hospitalisation of these individuals, providing greater longevity associated with the transplanted organ and enhanced quality of life for these individuals.'

Introduzione (Teaser)

Delayed graft function (DGF) is a condition that often follows organ transplantation. A novel antibody treatment may prevent graft rejection following transplantation by targeting DGF.

Altri progetti dello stesso programma (FP7-HEALTH)

EPC-TM-NET (2011)

Targeting the tumour microenvironment to improve pancreatic cancer prognosis

Read More  

DEVANX (2008)

Serotonin and GABA-B receptors in anxiety : from developmental risk factors to treatment

Read More  

PAR (2010)

Predicting antibiotic resistance

Read More